etranacogene dezaparvovec Hemgenix
Selected indexed studies
- Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. (N Engl J Med, 2023) [PMID:36812434]
- ** (, 2024) [PMID:39466920]
- ** (, 2024) [PMID:38985922]
_Worker-drafted node — pending editorial review._
Connections
etranacogene dezaparvovec Hemgenix is a side effect of
Sources
- Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. (2023) pubmed
- Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency). (2023) pubmed
- Gene therapy for hemophilia. (2022) pubmed
- Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial. (2024) pubmed
- Etranacogene Dezaparvovec: First Approval. (2023) pubmed
- Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B. (2026) pubmed
- PMID:39466920 (2024) pubmed
- Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B. (2023) pubmed
- PMID:38985922 (2024) pubmed
- New Drug Capsule: etranacogene dezaparvovec. (2023) pubmed